????5. 羅氏公司

????? 2013年研發(fā)支出：100億美元

????? 占收入的百分比：19%

????這家瑞士生物制藥公司的研發(fā)支出金額在醫(yī)療保健行業(yè)處于首位。三年前，羅氏公司（Roche）曾在這份榜單中登頂。和那時(shí)相比，該公司目前為研發(fā)投入了更多的資金，而且絕大多數(shù)（幾乎達(dá)到90%）都用在了藥品研制領(lǐng)域，其余資金則投向了診斷產(chǎn)品研發(fā)。羅氏最大的業(yè)務(wù)是抗腫瘤藥物，約占藥品研發(fā)支出的一半。該公司用于治療晚期癌癥的靶向新藥Kadcyla去年在美國和歐洲獲得批文。羅氏稱，該公司正在考慮將Kadcyla的部分平臺（比如創(chuàng)造性地實(shí)現(xiàn)了化療藥物和抗體的偶聯(lián)）用于今后的藥物研發(fā)。

????5. Roche

????? R&D spending in 2013: $10 billion

????? As a percentage of revenue: 19%

????Leading the healthcare industry in R&D spending, the Swiss biopharmaceutical company spends more today than it did when it topped the Strategy& list three years ago. The company invests an overwhelming majority of its R&D budget —almost 90%—on pharmaceuticals, while the rest goes into diagnostics. Oncology, the largest part of Roche’s business, eats about half of its pharma R&D spending. One of the company’s latest drugs, a targeted medicine for advanced breast cancer called Kadcyla, was approved in the U.S. and E.U. last year. Roche says it is looking to leverage parts of the Kadcyla platform (for instance, the innovative way it links chemotherapeutic agents and antibodies) for future drugs.